Penn State Health will discontinue its troubled liver and kidney transplant programs amid scrutiny from federal regulators. This comes only months after the programs relaunched following serious disciplinary sanctions.

A group of researchers evaluated the association between soft drinks consumption and the risk of NAFLD in a cohort of Mexican adults, primarily consisting of employees of the Mexican Social Security Institute (IMSS) and their relatives.

Advances in the clinical management of cholestasis have focused on mitochondrial dysfunction and bile acid metabolism. This review discusses several novel therapeutic agents that have shown promise in treating cholestasis by modulating these pathways.

The FDA identified cases of serious liver injury among patients being treated for primary biliary cholangitis (PBC) with Ocaliva (obeticholic acid) who did not have cirrhosis of the liver.

The review underscores the need for rigorous experimental validation and a nuanced understanding of cell death mechanisms in liver diseases.

GLP-1 receptor agonists emerge as promising therapies for MASLD, addressing metabolic dysfunction and offering potential improvements in liver health and fibrosis management.

A new study analyzing populations in Spain and the United States shows that even moderate alcohol consumption heightens the risk of liver fibrosis when paired with metabolic conditions in people with MASLD.

Many individuals worldwide suffer from chronic liver disease (CLD), which poses significant concerns for its tendency to lead to hepatocellular carcinoma or liver failure.

The CLA recently exhibited at the Pittsburgh Second Annual Gastrointestinal Cancer Summit. Here are a few pictures from the event!

A new study by researchers at Yale School of Medicine (YSM), published Aug. 27 in the journal Cell Metabolism, finds that people with MASLD burn fat in their livers at the same rate as people without the disease.

Hepatitis D (HDV) only infects people who have hepatitis B. And this form of hepatitis continues to be the most virulent and can quickly decompensate to liver disease.

A study by researchers from the Icahn School of Medicine at Mount Sinai reveals that prenatal exposure to environmental chemicals and endocrine disruptors may pose significant risks to liver health for both mothers and their newborns.

The "Liver Cirrhosis - Global Clinical Trials Review, 2024" clinical trials has been added to s offering.

A greater abundance of the bacterium in the first six months of life was significantly associated with less liver damage and an 84% lower likelihood of needing a liver transplant.

In a damning emergency order from the Florida DOH, Dr. Thomas Shaknovsky is said to have removed Alabama resident Bill Bryan's liver instead of his spleen in a "grievous medical error" that makes him an "immediate, serious danger" to the public.

The PFIC would like your thoughts about PFIC so they can determine what types of projects the PFIC Network should include in a research agenda. Complete the survey by December 23rd and you’ll receive a $15 gift card.

The EHB loophole is putting patients at risk. A letter led by @NCLadvocacy calls on @HHSGov @USTreasury & @USDOL to issue rulemaking that closes this harmful gap, ensuring all patients are protected from high out-of-pocket costs for specialty medications.

Using a novel stem cell platform, a team of MUSC researchers has identified a pathway that could be targeted by drugs to reduce fat accumulation in patients with a common form of fatty liver disease known as MASLD.

Today, as we celebrate the spirit of generosity, we invite you to join us in making a difference for individuals and families affected by liver disease. Your support helps the CLA provide vital resources, education, and advocacy for those who need it most.

The FDA is warning that Veozah (fezolinetant), a medicine used to treat hot flashes due to menopause, can cause rare but serious liver injury.